Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1589597

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1589597

Drug & Gene Delivery Devices Market by Route of Administration (Inhalation, Injectable, Nasal), Method (Ex vivo, In situ), Vector - Global Forecast 2025-2030

PUBLISHED:
PAGES: 190 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Drug & Gene Delivery Devices Market was valued at USD 4.33 billion in 2023, expected to reach USD 4.79 billion in 2024, and is projected to grow at a CAGR of 10.72%, to USD 8.83 billion by 2030.

The market for Drug & Gene Delivery Devices encompasses a wide range of systems used to deliver pharmaceutical compounds and genetic materials directly into a patient's system, ensuring targeted therapy with minimal side effects. Future scope lies in advancing precision medicine, where these devices could become pivotal in personalized treatments for chronic and genetic diseases. The necessity for these devices stems from the growing prevalence of chronic and genetic disorders and an increasing emphasis on minimally invasive delivery techniques. Applications vary across therapeutic areas, including oncology, diabetes, and infections, with end-use segments covering hospitals, clinics, and home care settings. Key growth factors influencing the market include advancements in biotechnology, growing demand for biologics, and innovations in nanotechnology which enhance delivery efficacy and patient compliance. Recent trends suggest potential opportunities in developing biodegradable and smart drug delivery systems that respond to physiological conditions for controlled release.

KEY MARKET STATISTICS
Base Year [2023] USD 4.33 billion
Estimated Year [2024] USD 4.79 billion
Forecast Year [2030] USD 8.83 billion
CAGR (%) 10.72%

Challenges include regulatory hurdles, high development costs, and potential biocompatibility issues. Limitations are further imposed by patent expirations of major drugs and stringent quality control requirements. The market exhibits a competitive nature, with substantial opportunities in research and development focused on improving delivery mechanisms such as micro-needles, hydrogels, and non-viral vectors for gene delivery. Stakeholders are encouraged to invest in cutting-edge technologies and cross-industry collaborations to enhance device functionality and patient outcomes. To capitalize on emerging opportunities, firms can explore partnerships for leveraging AI and big data analytics in improving personalized delivery systems. Innovations are best focused on multifunctional delivery platforms that integrate diagnostics and therapeutic functions, thereby strengthening efficacy and patient adherence. The evolving landscape in precision medicine and biologics demands continuous research and innovation, paving the way for strategic market entry points and sustained business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug & Gene Delivery Devices Market

The Drug & Gene Delivery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence rate of cardiovascular disorders (CVDs) and lifestyle disorders
    • Introduction of auto-injectors and advanced pulmonary devices
    • Rise in the consumption of drugs and therapeutic pharmaceuticals
  • Market Restraints
    • Increase in complications and expertise required in delivering therapeutics and drugs
  • Market Opportunities
    • Advancements in the field of drug and gene delivery systems such as smart nanoparticle technology, liposomes & hydrogels, and three-dimensional printing
    • Increasing ongoing research and development in the field of genomics for the development of gene delivery systems
  • Market Challenges
    • Increasing cost of high-end products

Porter's Five Forces: A Strategic Tool for Navigating the Drug & Gene Delivery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug & Gene Delivery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug & Gene Delivery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug & Gene Delivery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug & Gene Delivery Devices Market

A detailed market share analysis in the Drug & Gene Delivery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug & Gene Delivery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug & Gene Delivery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug & Gene Delivery Devices Market

A strategic analysis of the Drug & Gene Delivery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug & Gene Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Antares Pharma, Inc., B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Eisai Co., Ltd., Enable Injections, Inc., Gerresheimer AG, Insulet Corporation, Johnson & Johnson Services Inc., Koninklijke Philips N.V., Merck KGaA, OraSure Technologies, Inc., Oxford BioMedica PLC, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Drug & Gene Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Inhalation, Injectable, Nasal, Ocular, Oral, Topical, and Transdermal.
  • Based on Method, market is studied across Ex vivo and In situ.
  • Based on Vector, market is studied across Non-viral and Viral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-A86604082727

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence rate of cardiovascular disorders (CVDs) and lifestyle disorders
      • 5.1.1.2. Introduction of auto-injectors and advanced pulmonary devices
      • 5.1.1.3. Rise in the consumption of drugs and therapeutic pharmaceuticals
    • 5.1.2. Restraints
      • 5.1.2.1. Increase in complications and expertise required in delivering therapeutics and drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the field of drug and gene delivery systems such as smart nanoparticle technology, liposomes & hydrogels, and three-dimensional printing
      • 5.1.3.2. Increasing ongoing research and development in the field of genomics for the development of gene delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Increasing cost of high-end products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug & Gene Delivery Devices Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Inhalation
  • 6.3. Injectable
  • 6.4. Nasal
  • 6.5. Ocular
  • 6.6. Oral
  • 6.7. Topical
  • 6.8. Transdermal

7. Drug & Gene Delivery Devices Market, by Method

  • 7.1. Introduction
  • 7.2. Ex vivo
  • 7.3. In situ

8. Drug & Gene Delivery Devices Market, by Vector

  • 8.1. Introduction
  • 8.2. Non-viral
  • 8.3. Viral

9. Americas Drug & Gene Delivery Devices Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Drug & Gene Delivery Devices Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Drug & Gene Delivery Devices Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. Antares Pharma, Inc.
  • 3. B. Braun SE
  • 4. Baxter International Inc.
  • 5. Becton, Dickinson and Company
  • 6. Eisai Co., Ltd.
  • 7. Enable Injections, Inc.
  • 8. Gerresheimer AG
  • 9. Insulet Corporation
  • 10. Johnson & Johnson Services Inc.
  • 11. Koninklijke Philips N.V.
  • 12. Merck KGaA
  • 13. OraSure Technologies, Inc.
  • 14. Oxford BioMedica PLC
  • 15. Sanofi S.A.
Product Code: MRR-A86604082727

LIST OF FIGURES

  • FIGURE 1. DRUG & GENE DELIVERY DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG & GENE DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG & GENE DELIVERY DEVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY OCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY IN SITU, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON-VIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VECTOR, 2018-2030 (USD MILLION)
  • TABLE 148. DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!